PDCD1 and prostate carcinoma: In 2010 the immune therapy cancer vaccine sipuleucel-T was approved by the US Food and Drug Administration (FDA) for men with metastatic castration resistant PC (mCRPC)2 and the ongoing early phase trials of programmed cell death protein-1 (PD-1) inhibitors have reported promising results in prostate cancer (PC)2–4.